Because nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit tumor growth in vitro , we investigated the association between NSAIDs and melanoma to determine if there was epidemiologic evidence of a chemopreventive effect from these medications. Three hundred twenty-seven subjects with incident melanoma and 119 melanoma-free controls completed a structured interview assessing melanoma risk factors. The unadjusted odds ratio (OR) for use of nonaspirin NSAIDs was 0.58 (95% CI 0.31–1.11), in a comparison of subjects with melanoma to controls. After adjustment for melanoma risk factors, the OR was 0.71 (95% CI 0.23–2.02). Aspirin users had an unadjusted OR of 0.85 (95% CI 0.45–1.69) and an adjusted OR of 1.45 (95% CI 0.44–4.74). In this pilot study, we found no evidence of a significant association between analgesic use and melanoma risk when potential confounders are assessed. Based on conflicting reports in the literature, meta-analysis may be appropriate.
CITATION STYLE
Jeter, J. M., Bonner, J. D., Johnson, T. M., & Gruber, S. B. (2011). Nonsteroidal Anti-Inflammatory Drugs and Risk of Melanoma. Journal of Skin Cancer, 2011, 1–4. https://doi.org/10.1155/2011/598571
Mendeley helps you to discover research relevant for your work.